"New-grad PharmD finishing my first year as staff pharmacist at a national retail chain at $128K base plus relief shifts at a secondary chain adding $22K. Total $150K W-2 across two chains. $215K of PharmD federal student loans on PAYE with $385/month payment. The first lender applied the 1% rule to the student loan balance ($2,150/month theoretical vs $385 actual), tried to qualify me on Physician Loan (which they didn’t realize pharmacists aren’t eligible for at their lender), and after we sorted that out, offered me $295K. Jim’s team aggregated both W-2s under B3-3.1-01 with proper 24-month documentation of each chain, applied B3-6-05 for the actual $385 PAYE payment, and ran Conventional Conforming. $585K close on a Plantation home in 32 days."
Pharmacist mortgage from a lender who reads retail chain W-2, hospital and clinical specialty income, relief/PRN supplementation, independent community pharmacy S-corp distributions, and PharmD student loan IDR as one income picture.
Working pharmacists (Doctor of Pharmacy, PharmD) carry a different mortgage qualifying profile from physicians, surgeons, NPs, and PAs. Per BLS OOH May 2024 data, U.S. pharmacists run a median wage of $137,480 with top 10% over $172,040. Specialty and ownership tiers exceed this: clinical specialty pharmacists with BPS board certifications (BCPS, BCOP for oncology, BCIDP for infectious disease, BCCP for cardiology, BCPP for psychiatry) in the $130K–$185K range; independent community pharmacy owners commonly $200K–$400K; specialty and compounding pharmacy owners $250K–$600K+. PharmD student loan burden runs $150K–$250K typical — substantially less than MD ($200K–$450K) but more than NP/PA ($80K–$200K). Income mechanics include retail chain W-2 (CVS, Walgreens, Walmart, Costco, Publix, Rite Aid), hospital pharmacy W-2, hospital clinical specialty pharmacist roles, relief/PRN W-2 from secondary chains, independent community pharmacy S-corp ownership, specialty and compounding pharmacy S-corp ownership, hospital pharmacy residency sign-on bonuses, and consulting income for clinical specialty pharmacists. A critical contrast with physicians, surgeons, and NPs/PAs: pharmacists are NOT eligible for Physician/Doctor Loan products at most specialty lenders — the optimal path is Conventional Conforming or Jumbo with proper B3-6-05 IDR-aware DTI treatment.
Stairway Mortgage qualifies working pharmacists on the full income picture — retail chain pharmacy W-2 from CVS, Walgreens, Walmart, Costco, Publix, Rite Aid, or regional chain employers under Fannie Mae B3-3.1-01 as continuing employment income with 24-month average, hospital pharmacy W-2 base salary with possible specialty premium for BPS board-certified clinical pharmacists (BCPS, BCOP, BCIDP, BCCP, BCPP) treated as variable income under B3-3.1-01, relief or PRN W-2 supplementation from secondary chain or hospital pharmacy employers aggregating under B3-3.1-01 with 24-month history, multi-shift pattern overtime and weekend differential pay treated as variable W-2 income, hospital pharmacy residency (PGY-1, PGY-2) signed forward employment contracts for new graduates transitioning to first attending pharmacist position, S-corp W-2 reasonable compensation plus K-1 distributions under Fannie Mae B3-3.4-02 for independent community pharmacy owners, specialty pharmacy owners (including expanding GLP-1 compounding pharmacy ownership), and traditional compounding pharmacy owners with USP <797>/<800> compliant operations, consulting 1099-NEC income for clinical specialty pharmacists providing pharmacy benefit consulting, formulary management, or expert witness work, $150K–$250K of PharmD federal student loans on income-driven repayment with actual servicer payments documented under Fannie Mae B3-6-05 instead of 1 percent of balance, and PSLF eligibility for pharmacists employed at 501(c)(3) nonprofit hospitals, VA Medical Centers, Indian Health Service, and county hospitals. A new-grad PharmD starting first CVS or hospital position, an established hospital clinical pharmacist with BCPS specialty certification, an independent community pharmacy owner with practice S-corp, a specialty compounding pharmacy owner, and a multi-source pharmacist combining hospital W-2 with relief work each get qualified using methods that fit their actual structure. The key contrast: pharmacists do NOT qualify for Physician/Doctor Loan products at most specialty lenders — Conventional Conforming or Jumbo with proper B3-6-05 IDR documentation is the typical optimal path. We pick the right door before we quote. Or skip ahead: browse every loan program, run numbers on 100+ mortgage calculators, or check today's rates. For the parent hub and other medical professional paths, see our medical professionals mortgage hub.
Key facts every pharmacist should know before applying for a mortgage.
Pharmacists are NOT typically eligible for Physician/Doctor Loan products at most specialty lenders — a key contrast with physicians, NPs, and PAs. The optimal mortgage path for pharmacists is Conventional Conforming or Jumbo with proper B3-6-05 IDR-aware DTI treatment for the PharmD student loan burden. We don’t waste time chasing Physician Loan products that won’t accept the pharmacist credential.
Under Fannie Mae B3-6-05, actual IDR payment from Federal Student Aid plans counts in DTI. For pharmacists with $150K–$250K of PharmD debt at $137K income, payments commonly run $400–$1,200/month on PAYE/SAVE/IBR vs $1,500–$2,500 under the 1% rule.
The American Pharmacists Association (APhA) represents pharmacists broadly. The American Society of Health-System Pharmacists (ASHP) represents hospital and health-system pharmacists. The National Association of Boards of Pharmacy (NABP) administers NAPLEX and MPJE licensure exams. ACPE accredits PharmD programs.
The Board of Pharmacy Specialties (BPS) certifies clinical specialty pharmacists across 14+ specialty areas including BCPS (Pharmacotherapy), BCOP (Oncology), BCIDP (Infectious Disease), BCCP (Cardiology), BCPP (Psychiatry), and BCACP (Ambulatory Care). Specialty certification supports premium income tier qualifying.
Pharmacist mortgage solutions for every career stage.
Each stage of a pharmacist career has its own qualifying logic. A new-grad PharmD starting first retail chain or hospital position has a different mortgage path than an established hospital clinical pharmacist with BCPS specialty certification, or an independent community pharmacy owner with S-corp K-1 distributions plus practice ownership equity.
New-grad PharmD (Years 1–2)
"Just completed PharmD program plus NAPLEX/MPJE licensure. Starting first retail chain (CVS, Walgreens, Walmart, Costco) or hospital pharmacy position. Sign-on bonus where offered."
- Annual income $115K–$140K W-2 first pharmacist position
- $150K–$250K PharmD federal student loans on PAYE or SAVE
- Sign-on $5K–$30K (hospital residency completion or chain recruitment)
- Conventional with B3-6-05 IDR-aware DTI
Established retail chain pharmacist (Years 3–10)
"Established staff or pharmacy manager at CVS, Walgreens, Walmart, Costco, Publix, Rite Aid, or regional chain. Stable W-2 with possible relief/PRN supplementation at secondary chain."
- Annual income $130K–$165K staff W-2 + relief/PRN supplementation
- Multi-W-2 stack from primary and secondary chain employment
- Pharmacy manager role typically adds $10K–$25K to staff base
- Conventional Conforming with multi-W-2 documentation
Hospital clinical specialty pharmacist (Years 3–10)
"Hospital or health-system pharmacist with BPS specialty board certification (BCPS, BCOP, BCIDP, BCCP, BCPP, BCACP). Premium specialty pay tier above retail chain median."
- Annual income $130K–$185K specialty premium W-2
- PGY-1 + PGY-2 hospital pharmacy residency typical training path
- BPS board certification supports premium tier qualifying
- PSLF eligible if nonprofit hospital employer
Independent community pharmacy owner
"Owner of independent community pharmacy in S-corp structure. Combines W-2 reasonable compensation with K-1 distributions. Often multi-generational family pharmacy ownership."
- Annual income $200K–$400K through S-corp ownership
- S-corp W-2 reasonable comp + K-1 distributions under B3-3.4-02
- 2-year 1120-S history with Form 1084 cash-flow addbacks
- SBA 7(a)/504 coordination for acquisition or expansion
Specialty / compounding pharmacy owner
"Owner of specialty pharmacy or compounding pharmacy operating under USP <797>/<800> standards. Often serving specialty disease populations, GLP-1 compounding, hormone replacement therapy, or veterinary compounding."
- Annual income $250K–$600K+ through specialty practice S-corp
- Specialty pharmacy growth driver: GLP-1, HRT, biologic, IV/sterile compounding
- S-corp W-2 + K-1 + possibly USP-compliant facility equity
- Conventional Jumbo or Super-Jumbo with multi-entity documentation
How we calculate qualifying income for your pharmacist mortgage.
Four methods cover almost every pharmacist file we’ve closed. The right method depends on your career stage, whether you maintain primary retail chain or hospital W-2 employment, the role of relief/PRN supplementation, and whether you operate an independent community pharmacy or specialty pharmacy S-corp.
Method 1 — Retail chain or hospital W-2 + IDR-aware DTI (the pharmacist default)
The dominant pattern for working pharmacists. Retail chain W-2 (CVS Health, Walgreens Boots Alliance, Walmart Health, Costco Pharmacy, Publix Pharmacy, Rite Aid, regional chain employers) or hospital pharmacy W-2 base salary qualifies under Fannie Mae B3-3.1-01 as continuous employment income with 24-month average. For hospital clinical specialty pharmacists with BPS board certifications (BCPS, BCOP, BCIDP, BCCP, BCPP, BCACP), specialty premium pay qualifies as variable income with 24-month average. Hospital pharmacy residency (PGY-1, PGY-2) signed forward employment contracts allow signed-contract qualifying treatment for new graduates transitioning to first attending pharmacist position. The critical mechanic across all methods is B3-6-05 IDR-aware DTI treatment for the $150K-$250K PharmD student loan burden.
Method 2 — Multi-W-2 stack (primary + relief/PRN secondary)
For pharmacists stacking multiple W-2 employments: primary chain or hospital position plus relief/PRN W-2 at secondary chain or hospital. Under Fannie Mae B3-3.1-01, each W-2 stream qualifies as continuing employment with 24-month average. Multi-chain relief work is particularly common for pharmacy managers and senior staff pharmacists who pick up additional shifts at competitor chains for premium relief rates. Overtime, weekend differential, and holiday premium pay qualifies as variable W-2 income with 24-month history. The aggregate often substantially exceeds the primary W-2 alone.
Method 3 — W-2 + consulting / clinical specialty 1099 self-employment
For pharmacists who supplement W-2 with consulting work: pharmacy benefit consulting, formulary management consulting, expert witness work, drug information consulting, or pharmaceutical industry advisory roles. Under B3-3.1-01, the hospital or chain W-2 qualifies with 24-month average. Under B3-3.3-02, consulting 1099 income aggregates as continuing Schedule C self-employment with 2-year history. Consulting income is less universal among pharmacists than among physicians but common for senior clinical specialists, BPS-certified pharmacists, and pharmacy benefit managers.
Method 4 — S-corp pharmacy ownership (independent, specialty, compounding)
For pharmacists operating independent community pharmacy, specialty pharmacy, or compounding pharmacy as S-corp owners. Under IRC Section 1361 and Fannie Mae B3-3.4-02, qualifying income combines S-corp W-2 reasonable compensation (typically $110K-$160K for pharmacy owner-operators) plus K-1 distributions from Form 1120-S with 2-year history. Form 1084 cash-flow addbacks recover non-cash depreciation on pharmacy compounding equipment under IRC Section 167, Section 179 expensing on robotic dispensing systems and clean-room compounding equipment, and amortization on practice goodwill from acquisitions. SBA 7(a)/504 coordination for pharmacy acquisitions or expansions runs parallel.
Which loan program fits your pharmacist mortgage situation.
Seven loan-program categories cover essentially every pharmacist file we’ve closed. The mix tilts heavily toward Conventional Conforming with B3-6-05 IDR treatment (since pharmacists are NOT typically eligible for Physician/Doctor Loan products).
Conventional Conforming (IDR-aware, primary)
- Pharmacists at typical income tier with PharmD student loan IDR
- Fannie Mae B3-6-05 uses actual IDR payment in DTI
- Loan limits to $766,550 (FL) 2024-25
Conventional Jumbo
- Specialty pharmacists and pharmacy owners
- Combines W-2 + K-1 + Form 1084 addbacks
- Loan amounts above conforming limits
Multi-W-2 Stack Conventional
- Pharmacists with primary + relief/PRN W-2 across chains
- B3-3.1-01 aggregation of primary + secondary W-2s
- 2-year history of each supplementary W-2 stream
S-Corp Self-Employed Conventional
- Independent community, specialty, or compounding pharmacy owners
- W-2 reasonable comp + K-1 distributions under B3-3.4-02
- Form 1084 addbacks for compounding equipment + Section 179
Multi-Source W-2 + 1099
- Pharmacists combining hospital W-2 + consulting 1099
- B3-3.1-01 W-2 + B3-3.3-02 self-employment combined
- 2-year history of consulting stream
Asset-Depletion Non-QM
- Senior pharmacists with accumulated reserves
- Liquid assets amortized over 360 months as implied income
- Useful during practice transitions or ownership shifts
FHA Conventional Alternative
- Tight-cash new-grad pharmacists needing max down-payment flex
- 3.5% down minimum, gift funds liberally accepted
- MIP cost vs conventional — compare carefully
The pharmacist mortgage in context: 6 forces shaping how pharmacists qualify.
Pharmacist mortgage qualifying sits at the intersection of retail pharmacy chain consolidation, the decline trend of independent community pharmacy ownership, mail-order and PBM disruption, the growth of specialty pharmacy and compounding pharmacy as alternative ownership paths, clinical specialty pharmacist role expansion through BPS certifications, and the broader healthcare workforce dynamics affecting all medical professions. Each force shapes what a working pharmacist’s qualifying picture looks like.
Force 1 — Retail pharmacy chain consolidation
The U.S. retail pharmacy market is dominated by a small number of national chains: CVS Health (CVS Pharmacy), Walgreens Boots Alliance (Walgreens), Walmart Health (Walmart Pharmacy), Costco Pharmacy, Publix Pharmacy (regional Southeast), Rite Aid (in ongoing restructuring), Kroger Pharmacy, Albertsons Companies pharmacy. Per APhA workforce data, retail chain employment is the dominant pharmacist setting nationally. The mortgage implication: retail chain W-2 income is highly predictable and well-documented through standard W-2 employment, simplifying the qualifying mechanic for the majority of working pharmacists.
Force 2 — Independent community pharmacy decline trend
Independent community pharmacy ownership has faced sustained pressure over the past two decades from chain consolidation, PBM reimbursement compression, and mail-order disruption. Per NABP data, approximately 19,000-20,000 independent community pharmacies still operate in the U.S., down from historical highs. Independent pharmacy owners who remain typically run higher-margin specialty operations (DME, compounding, clinical services, niche populations) or community pharmacies in rural and underserved settings where chain presence is limited. The mortgage implication: independent pharmacy owners are typically running specialty or rural operations with stable but moderate K-1 distributions under B3-3.4-02.
Force 3 — Mail-order and PBM disruption
Mail-order pharmacy through Pharmacy Benefit Managers (Express Scripts, OptumRx, CVS Caremark) and direct-to-patient platforms (Amazon Pharmacy, Capsule, Alto Pharmacy, GoodRx Care) has reshaped the retail pharmacy landscape. Mail-order serves 90-day maintenance prescription fills, displacing significant retail chain volume. Pharmacist roles in PBM and mail-order operations include clinical pharmacist review, formulary management, and prior-authorization specialty positions. The mortgage implication: PBM and mail-order pharmacist W-2 income qualifies the same as retail or hospital W-2 under standard B3-3.1-01 employment treatment.
Force 4 — Compounding and specialty pharmacy growth
Compounding pharmacy and specialty pharmacy ownership represent the growth segment of pharmacy entrepreneurship. Drivers include: GLP-1 semaglutide and tirzepatide compounding (during FDA shortage list periods), bioidentical hormone replacement therapy (BHRT), sterile IV compounding for infusion practices and home infusion, veterinary compounding, ophthalmology compounding, and specialty disease state management. USP <797> (sterile compounding) and <800> (hazardous drug compounding) compliance requirements drive equipment investment and operational sophistication. The mortgage implication: specialty and compounding pharmacy owners commonly run $250K-$600K+ S-corp income tier with sophisticated equipment depreciation requiring Form 1084 addbacks.
Force 5 — Clinical specialty pharmacist role expansion through BPS certification
Per Board of Pharmacy Specialties (BPS), clinical specialty board certifications have expanded substantially over the past two decades. BCPS (Pharmacotherapy) is the largest specialty certification with over 30,000 BCPS-certified pharmacists. Additional specialties include BCOP (Oncology), BCIDP (Infectious Disease), BCCP (Cardiology), BCPP (Psychiatry), BCACP (Ambulatory Care), BCGP (Geriatric), BCPPS (Pediatric), BCSCP (Sterile Compounding), BCEMP (Emergency Medicine), and others. Clinical specialty pharmacists at hospitals and health systems command premium income tiers. The mortgage implication: BPS-certified specialty pharmacists qualify in the $130K-$185K income tier, comfortably supporting jumbo qualifying.
Force 6 — PharmD vs other medical doctorate income comparison
Pharmacists hold the PharmD doctoral degree but operate in a substantially different mortgage qualifying landscape than physicians (MD/DO), surgeons, and even NPs/PAs. The key contrast: pharmacists are NOT eligible for Physician/Doctor Loan products at most specialty lenders. Some specialty lenders extend pharmacy-specific products to PharmDs but these are less common than Physician Loan extension to NPs/PAs. The optimal mortgage path for pharmacists is typically Conventional Conforming or Jumbo with B3-6-05 IDR documentation. This affects down-payment flexibility (typically 5-20% conventional vs 0-10% Physician Loan), PMI requirements (PMI on <20% down vs no-PMI Physician Loan), and product structure. Working within the Conventional framework with proper documentation produces strong outcomes — we just don’t pretend Physician Loan is available when it isn’t.
Pharmacist mortgage by career stage.
A timeline view of how the right mortgage program changes as you progress from new-grad PharmD through established staff pharmacist to clinical specialty or independent pharmacy owner.
New-grad PharmD
Comp profile: $115K–$140K W-2 first position at retail chain or hospital pharmacy, with $5K–$30K sign-on possible. Dominant qualifying method: Conventional with B3-6-05 IDR-aware DTI. Common purchase: $400K–$650K primary residence. Watch-out: $150K–$250K of PharmD student loans require IDR enrollment AND properly-documented servicer statement showing actual monthly payment for B3-6-05 treatment. PSLF qualifying payments accruing if at nonprofit hospital.
Established staff or clinical specialty pharmacist
Comp profile: $130K–$185K W-2 across retail chain manager, hospital staff pharmacist, or hospital clinical specialty pharmacist with BPS board certification. Possibly supplementing with relief/PRN W-2 at secondary chain. Dominant qualifying method: Conventional Conforming or Jumbo with B3-3.1-01 W-2 stacking. Common purchase: $500K–$900K primary residence. Watch-out: Relief/PRN supplementation requires 2-year history. New relief arrangements within past 24 months may not yet count toward qualifying.
Independent community pharmacy owner
Comp profile: $200K–$400K through S-corp combining W-2 reasonable compensation plus K-1 distributions from established community pharmacy practice. Dominant qualifying method: S-Corp Self-Employed Conventional with B3-3.4-02 and Form 1084 addbacks. Common purchase: $700K–$1.4M primary residence. Watch-out: Equipment depreciation on robotic dispensing systems and clean-room equipment requires Form 1084 cash-flow analysis to restore qualifying income.
Specialty or compounding pharmacy owner
Comp profile: $250K–$600K+ through specialty practice S-corp with possibly significant equipment investment for USP <797>/<800> compliance. Specialty growth drivers include GLP-1 compounding, HRT, sterile IV compounding, and veterinary compounding. Dominant qualifying method: Conventional Jumbo or Super-Jumbo with multi-entity if multi-location practice. Common purchase: $1M–$2.4M primary residence. Watch-out: Specialty pharmacy regulatory environment (FDA shortage list status for GLP-1 compounding, state board compounding compliance) creates revenue volatility that requires 2-3 year trending documentation.
What pharmacists say about their Stairway mortgage.
Names abbreviated for client privacy. Practice details anonymized. Numbers are real.
"Hospital clinical oncology pharmacist for 7 years, BCPS and BCOP dual board certifications. Hospital W-2 at $172K (specialty premium tier) plus pharmacy benefit consulting 1099-NEC at $35K annually from a managed care organization. Total $207K across W-2 and consulting. Working at a nonprofit hospital with PSLF qualifying payments accruing. $185K of remaining PharmD student loans on PAYE with $625/month payment. The first lender said pharmacists don’t qualify for Physician Loan (correct), then applied the 1% rule to the loan balance ($1,850/month theoretical) and offered $385K Conventional. Jim’s team treated the hospital W-2 under B3-3.1-01 with proper specialty premium documentation, aggregated the PBM consulting 1099 under B3-3.3-02 as continuing self-employment, applied B3-6-05 for the actual $625 PAYE payment with PSLF context, and ran Conventional Jumbo. $895K close on a Weston home in 38 days."
"Independent compounding pharmacy owner for 11 years. Specialty focus on bioidentical hormone replacement therapy, sterile IV compounding for infusion practices, and veterinary compounding. USP <797> and <800> compliant facility. S-corp structure with $145K reasonable-comp W-2 plus $385K in K-1 distributions. Total $530K through W-2 plus K-1. Significant compounding equipment investment with Section 179 expensing of $215K in the past year (new sterile compounding clean-room equipment). The first lender saw the equipment-suppressed taxable income and refused to count the addbacks, called the specialty pharmacy ‘risky industry,’ and offered me $580K. Jim’s team aggregated the W-2 plus K-1 under B3-3.4-02, ran Form 1084 addbacks for the Section 179 compounding equipment expensing and depreciation, documented the USP compliance and specialty pharmacy revenue stability, and qualified me on the full picture. $1.45M close on a Coral Springs home in 47 days. The income is real and verifiable from day one — compounding pharmacy ownership just needs a broker who understands the equipment investment economics."
Pharmacist mortgage questions, answered.
More pharmacist mortgage resources at Stairway
More on pharmacist mortgages, BPS specialty premium, and pharmacy ownership.
Other medical paths
Loan-program details
Calculators & tools
Sources & further reading.
APhA / ASHP / NABP / ACPE / BPS & pharmacist industry
- American Pharmacists Association (APhA)
- American Society of Health-System Pharmacists (ASHP)
- National Association of Boards of Pharmacy (NABP) — NAPLEX/MPJE
- Accreditation Council for Pharmacy Education (ACPE)
- Board of Pharmacy Specialties (BPS) — BCPS, BCOP, BCIDP, etc.
- United States Pharmacopeia (USP) — <797>/<800> compounding standards
IRS & tax guidance
Cornell Law — statutory references
Mortgage program & student loan guidelines
- Fannie Mae B3-3.1-01 — Variable Income (chain W-2 + relief)
- Fannie Mae B3-3.3-02 — Schedule C Self-Employed (consulting)
- Fannie Mae B3-3.4-02 — S-Corp (pharmacy ownership)
- Fannie Mae B3-6-05 — Monthly Debt Obligations (IDR)
- Federal Student Aid — Income-Driven Repayment
- Federal Student Aid — PSLF for VA/Hospital Pharmacists
- SBA 7(a) — Pharmacy Acquisition Financing
Pharmacist mortgage, structured right.
Established hospital clinical oncology pharmacist, 7 years post-PGY-2 oncology fellowship, dual BPS board certifications (BCPS Pharmacotherapy and BCOP Oncology). Hospital W-2 at a nonprofit cancer center at $172K specialty premium tier plus pharmacy benefit consulting 1099-NEC at $35K annually from a regional managed care organization providing formulary review for oncology drugs. Total $207K across W-2 and consulting with consistent 2-year history. Plus $185K of remaining PharmD federal student loans on PAYE plan with documented servicer payment of $625/month based on $172K W-2 income. Working at the nonprofit cancer center qualifies for PSLF qualifying payments, with the 10-year clock having started in residency 9 years prior. The first lender said pharmacists don’t qualify for Physician Loan (correct — this lender did not extend Physician Loan to PharmDs), but then applied the 1% rule to the student loan balance ($1,850/month theoretical vs $625 actual), refused the consulting 1099 as "supplementary not continuing," didn’t apply the BPS board certification context to support the specialty premium income tier, and offered $385K maximum Conventional. We pulled the hospital employment letter documenting the BCPS and BCOP specialty pharmacist role and the $172K W-2 history, the pharmacy benefit consulting agreement with 2-year billing history, the IDR servicer statement showing the $625 actual PAYE payment with PSLF context, the BPS specialty board certification verification, the PharmD degree and NAPLEX/MPJE licensure documentation. Ran the hospital W-2 through Fannie Mae B3-3.1-01, aggregated the pharmacy benefit consulting 1099 under B3-3.3-02 as continuing Schedule C self-employment with 2-year history, and applied B3-6-05 for the actual $625 PAYE payment with PSLF documentation. Total qualifying income: $203K (after normalization on the consulting stream). Approved at $895K conventional jumbo for a Weston home. Closed in 38 days. Pharmacists with BPS specialty certifications and PSLF-eligible nonprofit hospital employment are exactly the borrower profile Conventional Jumbo with proper documentation handles well — the first lender just didn’t know how to read the specialty premium tier plus consulting plus IDR pattern.
Get a pharmacist mortgage from a lender who reads retail chain W-2, hospital clinical specialty, relief/PRN stacking, independent and specialty pharmacy S-corp, and PharmD IDR as one file — without wasting time chasing Physician Loan products pharmacists can’t access.
No application. No credit pull. A 20-minute conversation where we look at your retail chain or hospital W-2, any relief/PRN secondary W-2s, any consulting 1099s, any pharmacy S-corp 1120-S returns and K-1s if independent or specialty pharmacy owner, your employment letter and BPS specialty certification if applicable, your IDR servicer statement, your PharmD degree and NAPLEX/MPJE licensure, and any state pharmacy permit if practice owner — then we tell you whether Conventional Conforming or Jumbo with proper B3-6-05 documentation fits best and roughly what the numbers look like. If we’re not the right shop, we’ll tell you that too.
Jim Blackburn NMLS #1072866 · Stairway Mortgage